MESO FY 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-21.3% YoY

Gross Profit

-$35M-595.9% margin

Operating Income

-$84M-1425.7% margin

Net Income

-$88M-1490.3% margin

EPS (Diluted)

$-0.89

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$49M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$669M

Total Liabilities

$189M

Stockholders' Equity

$480M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$8M	-21.3%
Gross Profit	-$35M	-$47M	+25.8%
Operating Income	-$84M	-$69M	-21.4%
Net Income	-$88M	-$82M	-7.4%